1. A method to protect an animal from a disease or condition that can be treated by granulocyte colony-stimulating factor (G-CSF), comprising administering to an animal having said disease or condition a composition comprising a cysteine variant of G-CSF of SEQ ID NO: 6, wherein said G-CSF cysteine variant comprises at least one cysteine residue substituted for at least one amino acid located in at least one region of G-CSF selected from the group consisting of: the A-B loop, the B-C loop, the C-D loop, the first three or last three amino acids in helix B, the first three or last three amino acids in helix C, the first three or last three amino acids in helix D, and the amino acids following helix D.
2. The method of claim 1, wherein said cysteine variant comprises at least one cysteine residue substituted for at least one amino acid selected from the group consisting of: K40, S53, G55, W58, A59, P60, S62, S63, P65, S66, Q67, A68, Q70, A72, Q90, A91, E93, G94, S96, E98, G100, G125, M126, A127, A129, Q131, T133, Q134, G135, A136, A139, A141, S142, A143, Q145, Q173 and P174.
3-59. (canceled)
60. An isolated, PEGylated granulocyte colony stimulating factor (G-CSF) variant of SEQ ID NO:6, wherein a polyethylene glycol is attached to the protein through an amino acid position, with respect to SEQ ID NO:6, selected from the group consisting of: 2, 6, 7, 58, 68, 93, 129, 131, 133, 134, 136, 139, 141, and 173, and wherein said variant has biological activity in vitro as measured by proliferation of a cell line that proliferates in response to G-CSF.
61. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to the protein through amino acid 2 of said G-CSF variant.
62. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 6 of said G-CSF variant.
63. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 7 of said G-CSF variant.
64. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 58 of said G-CSF variant.
65. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 68 of said G-CSF variant.
66. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 93 of said G-CSF variant.
67. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 129 of said G-CSF variant.
68. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 131 of said G-CSF variant.
69. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 133 of said G-CSF variant.
70. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 134 of said G-CSF variant.
71. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 136 of said G-CSF variant.
72. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 139 of said G-CSF variant.
73. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 141 of said G-CSF variant.
74. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to amino acid 173 of said G-CSF variant.
75. The isolated, PEGylated G-CSF variant of claim 60, wherein the variant is monoPEGylated.
76. The isolated, PEGylated G-CSF variant of claim 60, wherein a non-cysteine residue is substituted for cysteine-17 of said G-CSF variant.
77. The isolated, PEGylated G-CSF variant of claim 76, wherein said non-cysteine amino acid is selected from the group consisting of serine and alanine.
78. The isolated, PEGylated G-CSF variant of claim 60, wherein a polyethylene glycol is attached to a cysteine residue substituted for the amino acid at said amino acid position.
79. A composition comprising at least one PEGylated granulocyte colony stimulating factor (G-CSF) variant according to claim 60.
80. A method to stimulate proliferation and differentiation of hematopoietic cells in an animal, comprising administering to said animal an isolated PEGylated granulocyte colony stimulating factor (G-CSF) variant of claim 60.
81. The method of claim 80, wherein said composition is administered by intravenous administration or subcutaneous administration.
82. The method of claim 80, wherein said animal has a deficiency of hematopoietic cells.
83. The method of claim 80, wherein said deficiency of hematopoietic cells is associated with myelosuppressive chemotherapy, bone marrow transplantation, infection with the human immunodeficiency virus, or chronic neutropenia.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound tent structure comprising:
a. a first saddle-shaped tent;
b. a second saddle-shaped tent;
wherein said first and said second saddle-shaped tents are juxtaposed in an end-to-end fashion; and
c. a portico interposed between an end of the first saddle-shaped tent and an end of said second saddle-shaped tent, wherein said portico comprises:
i. a drape having a lower edge, wherein said drape hangs downward from said first and said second saddle-shaped tents and connects said first saddle-shaped tent to said second saddle-shaped tent; and
ii. a portico-frame comprising at least two generally vertical posts and at least one horizontal beam defining an opening of such height and width to allow human beings to ingress into and egress from said compound tent structure, wherein said horizontal beam is attached to at least a portion of said lower edge of said drape such that said lower edge is attached to said beam along a portion of its length, wherein each of said posts has an upper end and a lower end, and wherein said upper end of each of said posts is connected to said horizontal beam and said lower end of each of said posts is supported by a surface.
2. The compound tent of claim 1 wherein said horizontal beam of said portico comprises a keder rail and wherein said lower edge of said drape is held within a track in said keder rail.
3. The compound tent structure of claim 2 wherein said portico, further comprises at least one panel.
4. The compound tent of claim 3 wherein said panel comprises a window.
5. The compound tent of claim 3 wherein said panel comprises a door.
6. A saddle-shaped tent comprising:
a frame including first and second arcuate frame members each having opposite ends, one end of the first frame member being supported by a surface adjacent one end of the second frame member, and the other end of the first frame member being supported by the surface adjacent the other end of the second frame member;
a canopy supported by the frame members such that the canopy forms a saddle shape and has opposite ends; and
a portico on at least one end of the canopy including a drape hanging down from the end of the canopy, the drape having a lower edge, and a portico-frame comprising at least two generally vertical posts and at least one horizontal beam defining an opening of such height and width to allow human beings to ingress into and egress from the tent, wherein the horizontal beam is attached to at least a portion of the lower edge of the drape such that the lower edge is attached to the beam, wherein each of the posts has an upper end and a lower end, and wherein the upper end of each of the posts is connected to the horizontal beam and the lower end of each of the posts is supported by the surface.
7. The tent of claim 6 wherein said horizontal beam of said portico comprises a keder rail and wherein said lower edge of said drape is held within a track in said keder rail.
8. The tent of claim 7 wherein said portico further comprises a panel.
9. The tent of claim 8 wherein said panel comprises a window.
10. The tent of claim 8 wherein said panel comprises a door.
11. The tent of claim 8 wherein said panel is substantially vertically oriented.
12. The tent of claim 7 wherein said portico further comprises a plurality of panels that form a portico wall.
13. The tent of claim 7 wherein said horizontal beam of said portico comprises interconnecting sections.